Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG + Cetuximab in KRAS WT Colorectal Cancer
NCT01309126Phase 3Terminated
- Sponsor
- HiberCell
- Start
- Apr 2011
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of odetiglucan in colorectal cancer (CRC), sponsored by HiberCell. Started Apr 2011; status: terminated.
02
Drugs
odetiglucan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01309126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01309126.